Price (delayed)
$89.96
Market cap
$5.14B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.3
Enterprise value
$5.13B
Glaukos (www.glaukos.com) is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. The company pioneered Micro-Invasive Glaucoma Surgery,
There are no recent dividends present for GKOS.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.